NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine

{
  "id": "MLC-T-ONC-015567",
  "term": "NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1 (NY-ESO-1(157-165)), with potential immunostimulatory and antineoplastic activities. Upon administration, the NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount both an anti-tumoral cytotoxic T-lymphocyte (CTL) and an antibody-mediated immune response against NY-ESO-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ny-eso-1-157-165-peptide-pulsed-autologous-dendritic-cell-vaccine/"
}